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Abstract
Background: A recent publication on efficacy of Sprifermin for knee osteoarthritis (OA) using quantitatively MRI-defined
central medial tibio-femoral compartment cartilage thickness as the structural primary endpoint reported no statistically
significant dose response. However, Sprifermin was associated with statistically significant, dose-dependent reductions in
loss of total and lateral tibio-femoral cartilage thickness. Based on these preliminary promising data a post-hoc analysis of
secondary assessment and endpoints was performed to evaluate potential effects of Sprifermin on semi-quantitatively
evaluated structural MRI parameters. Aim of the present analysis was to determine effects of sprifermin on several knee
joint tissues over a 12 month period.
Methods: 1.5 T or 3 T MRIs were acquired at baseline and 12 months follow-up using a standard protocol. MRIs were
read according to the Whole-Organ Magnetic Resonance Imaging Score (WORMS) scoring system (in 14 articular
subregions) by four muskuloskeletal radiologists independently. Analyses focused on semiquantitative changes in
the 100 μg subgroup and matching placebo of multiple MRI-defined structural alterations. Analyses included a
delta-subregional and delta-sum approach for the whole knee and the medial and lateral tibio-femoral (MTFJ,
LTFJ), and patello-femoral (PFJ) compartments, taking into account number of subregions showing no change,
improvement or worsening and changes in the sum of subregional scores. Mann–Whitney −Wilcoxon tests
assessed differences between groups.
Results: Fifty-seven and 18 patients were included in the treatment and matched placebo subgroups. Less worsening
of cartilage damage was observed from baseline to 12 months in the PFJ (0.02, 95 % confidence interval (CI) (−0.04, 0.08)
vs. placebo 0.22, 95 % CI (−0.05, 0.49), p = 0.046). For bone marrow lesions (BMLs), more improvement was observed
from 6 to 12 months for whole knee analyses (−0.14, 95 % CI (−0.48, 0.19) vs. placebo 0.44, 95 % CI (−0.15, 1.04), p = 0.
042) although no significant effects were seen from the baseline visit, or in Hoffa-synovitis, effusion-synovitis, menisci and
osteophytes.
Conclusions: In this post-hoc analysis cartilage showed less worsening from baseline to 12 months in the PFJ, and BMLs
showed more improvement from 6 to 12 months for the whole knee.
Trial registration: ClinicalTrials.gov identifier: NCT01033994.
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Background
The treatment of knee OA is currently restricted to
management of pain and function with low-to-moderate
efficacy. The potential of a combined beneficial effect on
joint structure and symptoms in OA as a result of treat-
ment with several pharmacologic compounds has been
investigated [1–4]. However, none of these agents has
been shown to have unequivocally beneficial effects on
structural characteristics that also translate into clinical
benefit [5]. Many studies have focused on use of antica-
tabolic agents to delay progression [5]. An alternative
approach is to stimulate cartilage development and re-
pair. Sprifermin (recombinant human fibroblast growth
factor 18; rhFGF18) binds to and specifically activates
fibroblast growth factor receptor 3 (FGFR-3) in cartilage
to promote chondrogenesis and cartilage matrix produc-
tion in vitro [6]. Preclinical data have shown that sprifer-
min stimulates chondrocyte proliferation, cartilage matrix
formation, and cartilage repair in vitro and in vivo [6, 7].
Recently, the results of a randomized, double-blind,
placebo-controlled phase 1b clinical trial of sprifermin in
knee OA were reported [8]. In that trial, no statistically
significant response was seen in the primary structural
endpoint, the central medial tibio-femoral compartment
cartilage thickness on quantitative MRI (qMRI) [8]. How-
ever, pre-specified secondary structural efficacy endpoints,
such as loss of total and lateral tibio-femoral cartilage
thickness, showed statistically significant dose-dependent
effects. Given the close interaction of the different tissues
on a local level within the joint and its relevance to struc-
tural progression [9], changes in cartilage surface morph-
ology may also be associated with an impact on the
subchondral bone and other joint structures.
For these reasons a post-hoc investigation taking into
account changes in multiple joint tissues based on semi-
quantitative scoring and using advanced analytic
approaches was conducted. The aim of this post-hoc
analysis was to determine effects of sprifermin on semi-




Details of study design and patient inclusion have been
reported [8]. In brief, in this multicenter, randomized,
double blind, placebo-controlled trial, (ClinicalTrials.gov
identifier: NCT01033994), sprifermin was evaluated as a
single treatment and as a multiple-dose regimen with
three doses of either 10 μg, 30 μg, or 100 μg with 21, 42
and 63 patients respectively, and matched placebo
groups of 7, 14 and 21 patients, respectively. Patients
were aged ≥40 years, had an established diagnosis of
primary tibio-femoral knee OA according to American
College of Rheumatology clinical and radiologic criteria,
with Kellgren-Lawrence (KL) grade 2 or 3 disease in the
target knee [10]. Altogether 477 patients were screened
and 192 were randomized (24 to the single-dose cohorts
and 168 to the multiple-dose cohorts. All patients in the
single-dose cohorts received treatment with the study
drug and completed the trial. All patients in the
multiple-dose cohorts received ≥1 dose of study medica-
tion, with 168 forming the modified intent-to-treat
population; 156 (92.9 %) completed the trial.
Similar to the recently reported post-hoc analysis on
quantitative cartilage parameters [11], the current sqMRI
analysis focuses on subjects with baseline and 12 month
data in the cohort that received sprifermin 100 μg (n = 57)
(since this was the dosing regimen on which significant
drug efficacy was observed [8]), and in those who
were randomized, in parallel, to receive matching placebo
(n = 18). Since this multicenter trial enrolled cohorts se-
quentially using a dose-ascending approach across 30 sites
on multiple continents [11], a comparison of the 100 μg
subgroup with a combined placebo subgroup incorporat-
ing all dosages (n = 42) was not warranted. The detailed
flow-chart of inclusion of the current analysis is presented
in Fig. 1.
Primary end points and assessments
The primary efficacy end point was the longitudinal
change from baseline in central medial tibio-femoral
compartment cartilage thickness at 6 months and
12 months, as assessed using qMRI [8].
Secondary end points and assessments
Secondary imaging end points included total and com-
partmental femorotibial cartilage thickness and volume
as assessed by qMRI, measurement of joint space width
by fixed-flexion weight-bearing radiography, and assess-
ment of bone marrow lesions (BMLs), cartilage, menisci,
osteophytes, effusion, and synovitis by sqMRI using the
modified Whole-Organ Magnetic Resonance Imaging
Score (WORMS) at baseline, 3, 6, and 12 months
follow-up [12].
MRI acquisition
MRIs were acquired using 1.5 T or 3 T systems. Axial,
coronal, and sagittal intermediate-weighted turbo or fast
spin–echo fat-suppressed sequences were used for semi-
quantitative whole joint assessment of structural tissue
pathology, with identical parameters, software and hard-
ware used at baseline and follow-up. Image parameters
were as follows: slice thickness 3.0 mm, in-plane resolution
0.55 × 0.55 mm, repetition time 3,600–4,000 msec, and
echo time 30–40 msec. In addition the double-oblique
coronal spoiled gradient-recalled sequences with fat
suppression or water excitation that were acquired for
cartilage thickness determination using quantitative MRI
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were considered for sqMRI assessment with the following
acquisition paramaters: contiguous slice thickness 1.5 mm,
in-plane resolutions 0.23 × 0.23 mm to 0.32 × 0.32 mm,
repetition time 18–50 msec, echo time 6.5–14 msec, flip
angle 15–20°.
MRI interpretation
Four musculoskeletal radiologists (FWR, AG, MDC,
MDM), with 7–16 years experience in standardized
sqMRI assessment of knee OA, graded cartilage status,
BMLs, osteophytes, effusion, synovitis and meniscal
morphology according to the WORMS system [12] with
blinding to treatment, radiographic OA grade and clinical
data. In addition to the published WORMS scale medial
and lateral meniscal extrusion was assessed on the coronal
plane according to previous publications [13, 14] and
graded as follows: 0 = no meniscal extrusion,1 = extru-
sion < 50 %, 2 = extrusion ≥ 50 %. Baseline and follow-
up MRIs were presented sequentially, with the
chronological acquisition order known to the readers. The
four readers assessed the images independently with an
equal number of examinations assigned to each reader.
Statistical analysis
Statistical analyses were performed using SAS software
(version 9.1; SAS Institute). Included in the current
analysis were patients from the 100 μg and matched
placebo subgroups with complete MRI datasets with all
features and subregions scorable. Analyses included
multi-dimensional assessment: (a) A delta-subregional
approach was applied, which adds the number of subre-
gions (total of 14 articular subregions for cartilage and
BMLs on a knee level, 5 subregions each for the medial
and lateral tibio-femoral [MTFJ, LTFJ] and 4 subregions
for the patello-femoral [PFJ] compartment) showing
worsening (>0), no change (0) or improvement (<0). As
an example, 5 subregions showing worsening, 7 subre-
gions showing improvement and 3 subregions showing
no change will result in a delta-subregion change of −2.
(b) In addition, a delta-sum approach was used, which
adds the absolute scores of all subregions combined per
compartment or for the whole knee. Analyses were per-
formed on a whole knee level and separately for MTFJ,
LTFJ and PFJ compartments for all subgroups. Mann–
Whitney −Wilcoxon tests assessed differences between
treatment groups. In sensitivity analysis adjusting for
baseline values, analysis of covariance (ANCOVA) on
ranked baseline and post baseline values was performed.
P-values were not adjusted for multiple testing.
Results
In regard to baseline demographic characteristics the
100 μg and matched placebo subgroup were comparable
without statistically significant differences in regard to age,
gender, BMI, KL grade and time since onset of OA. The
detailed patient demographics are presented in Table 1.
For change in cartilage surface morphology from base-
line to 12 months, statistically significant differences
with less worsening in the treatment group were ob-
served in the PFJ (delta-sum approach; treatment 0.05,
95 % CI (−0.06, 0.17) vs. placebo 0.44, 95 % CI (−0.18,
1.06), p = 0.048; delta-subregional approach; treatment
(0.02 95 % CI (−0.04, 0.08) vs. placebo 0.22, 95 % CI
(−0.05, 0.49), p = 0.046). Although baseline values were
statistically different, after adjusting for baseline in
Fig. 1 Detailed flow-chart of subject inclusion to the 100 μg subgroup






Age, mean (standard deviation) 61.2 (9.1) 60.9 (6.9)
Sex, no. (%) female 39 (68.4) 12 (66.7)
Body mass index (standard deviation) 30.5 (5.0) 31.5 (5.3)
Kellgren-Lawrence grade 3 (%) 29 (50.9) 11 (61.1)
Time since onset of osteoarthritis,
years (standard deviation)
7.1 (5.4) 7.4 (3.7)
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ANCOVA sensitivity analysis, results remained statistically
significant at a significance level of 0.05.
For change in BMLs from baseline to 12 months
only, no significant findings were seen for either
treatment or placebo groups using both analytic
approaches.
The details of the baseline to 12 months analyses for
cartilage and BMLs are presented in Table 2.
For BMLs, in post-hoc evaluation, all interim visits were
analyzed in a non-preplanned time frame. Statistically
significant changes in BMLs in favor of the treatment
group were observed for the whole knee from 6 to
12 months (delta-subregional approach; treatment −0.14,
95 % CI (−0.48, 0.19) vs. placebo 0.44, 95 % CI (−0.15,
1.04), p = 0.042), and were borderline for the LTFJ (delta-
sum approach; treatment −0.13, 95 % CI (−0.39, 0.14) vs.
placebo 0.22, 95 % CI (−0.10, 0.54), p = 0.062; delta-
subregion approach: −0.05, 95 % CI (−0.27, 0.16) vs
placebo 0.22, 95 % CI (−0.10, 0.54), p = 0.064). The
detailed BML analyses for the different intervals are
presented in Table 3. For all other analyzed parameters
including meniscus, osteophytes, effusion-synovitis and
Hoffa-synovitis, no significant changes from baseline to
12 months or between groups were observed.
Discussion
In this post-hoc analysis of the effects of sprifermin on
cartilage and non-cartilaginous joint tissues, the most
notable finding was that cartilage surface morphology
showed less worsening from baseline to 12 months in
the PFJ, and that BMLs analyzed for the whole knee
showed improvement after 100 μg sprifermin treatment
from 6 to 12, but not from baseline to 6 months. For
other parameters, subregional analyses and observation
intervals, the results were not significant, ─ possibly a
consequence of small numbers, which make statistical
interpretation challenging.
In light of the previous trials showing more marked
treatment effects on cartilage in the lateral knee com-
partment as compared to the medial knee compartment
[15, 16], it is interesting to note that in this analysis
using subregional analytic approaches, a non-significant
tendency toward less worsening in the lateral femoroti-
bial compartment (LTFC) as compared to the medial
femorotibial compartment (MTFC) was observed. The
reasons for the seemingly preferential effect on the
lateral knee compartment in the present and previous
studies are still under debate. Commonly, the medial
compartment is subjected to more loading and is also
more severely affected by OA. Consequently, an anabolic
agent acting on cartilage may be less effective in areas of
mechanical challenge that are already severely damaged,
such as the medial compartment.
A strong association between BMLs and cartilage
surface morphology has been shown in previous work
using subregional semi-quantitative approaches [9, 17].
While no definitive effects on BML change were seen
from baseline to 12 months, more improvement of
BMLs was shown from 6 to 12 months for the whole
knee analysis, a finding that is not easily explained.
Whether cartilage alterations may have secondary
biomechanical effects on the adjacent subchondral
bone, which may lead to a decrease in localized load-
ing and regression of BMLs remains to be shown
Table 2 Cartilage morphology and bone marrow lesion ─ baseline and change from baseline to 12 months
Cartilage morphology Bone marrow lesion
100 μg cohort (n = 57)
mean (95 % CI)
Matched placebo (n = 18)
mean (95 % CI)
p - value 100 μg cohort (n = 56)
mean (95 % CI)
Matched placebo (n = 18)
mean (95 % CI)
p - value
Whole knee Baseline 21.1 (17.2, 25.0) 30.0 (22.0,37.9) 0.040* 3.3 (2.5, 4.1) 3.3 (1.4, 5.2) 0.642
Delta sum 0.42 (0.00, 0.84) 0.94 (−0.34, 2.23) 0.362 −0.20 (−0.67, 0.28) 0.22 (−0.62, 1.07) 0.237
Delta subregion 0.19 (−0.01, 0.40) 0.44 (−0.24, 1.13) 0.371 −0.23 (−0.60, 0.14) 0.22 (−0.43, 0.87) 0.113
LTFJ Baseline 4.5 (2.6, 6.4) 7.6 (3.8, 11.5) 0.019* 0.7 (0.3, 1.1) 0.7 (0.0, 1.4) 0.981
Delta sum 0.07 (−0.16, 0.30) 0.17 (−0.09, 0.42) 0.342 0.04 (−0.16, 0.23) 0.11 (−0.05, 0.27) 0.242
Delta subregion 0.05 (−0.07, 0.18) 0.11 (−0.05, 0.27) 0.349 0.04 (−0.13, 0.20) 0.17 (−0.02, 0.36) 0.107
MTFJ Baseline 9.3 (7.2, 11.5) 11.5 (7.3, 15.8) 0.352 1.6 (1.1, 2.2) 1.1 (0.3, 1.9) 0.418
Delta sum 0.30 (−0.04, 0.64) 0.33 (−0.28, 0.95) 0.690 −0.11 (−0.50, 0.28) 0.11 (−0.52, 0.75) 0.469
Delta subregion 0.12 (−0.03, 0.27) 0.11 (−0.27, 0.49) 0.712 −0.13 (−0.40, 0.15) 0.06 (−0.34, 0.45) 0.510
PFJ Baseline 7.3 (5.6., 9.1) 10.8 (7.5, 14.1) 0.038* 1.0 (0.5, 1.5) 1.5 (0.1, 2.9) 1.000
Delta sum 0.05 (−0.06, 0.17) 0.44 (−0.18, 1.06) 0.048* −0.13 (−0.34, 0.09) 0.00 (−0.38, 0.38) 0.368
Delta subregion 0.02 (−0.04, 0.08) 0.22 (−0.05, 0.49) 0.046* −0.14 (−0.34, 0.06) 0.00 (−0.38, 0.38) 0.352
CI confidence interval, LTFJ lateral tibio-femoral joint (includes 5 subregions), MTFJ medial tibio-femoral joint (includes 5 subregions), PFJ patello-femoral joint
(includes 4 subregions). Possible score range for each subregion at baseline and 12-month is 0–3 and 0–6 for bone marrow lesion and cartilage morphology,
respectively
*Statistically significant at p ≤ 0.05
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[18]. Fluctuations of BMLs have been observed,
focusing attention on BMLs as potential treatment
targets [3, 16]. The finding that sprifermin may have
indirect or direct effects on the subchondral bone
hence warrants further exploration.
Finally, no significant changes between treatment and
placebo groups were seen for other joint parameters
including osteophytes, meniscal pathology, effusion, and
synovitis. This may be explained by the pharmacologic
mode of action of sprifermin targeting cartilage, the slow
Table 3 Bone marrow lesion changes between interim visits
100 μg cohort (n = 56)
Mean (95 % CI)
Matched placebo (n = 18)
Mean (95 % CI)
p - value
Whole knee Baseline 3.3 (2.5, 4.1) 3.3 (1.4, 5.2) 0.642
Delta sum
0 to 3 months −0.02 (−0.38, 0.34) −0.17 (−0.85, 0.52) 0.682
3 to 6 months −0.04 (−0.41, 0.34) −0.06 (−0.37, 0.26) 0.933
6 to 12 months −0.14 (−0.54, 0.26) 0.44 (−0.15, 1.04) 0.054
Delta subregion
0 to 3 months 0.02 (−0.28, 0.32) −0.22 (−0.87, 0.43) 0.597
3 to 6 months −0.05 (−0.37, 0.27) −0.06 (−0.37, 0.26) 0.911
6 to 12 months −0.14 (−0.48, 0.19) 0.44 (−0.15, 1.04) 0.042*
LTFJ Baseline 0.7 (0.3, 1.1) 0.7 (0.0, 1.4) 0.981
Delta sum
0 to 3 months 0.04 (−0.12, 0.19) 0.00 (−0.17, 0.17) 0.859
3 to 6 months 0.13 (−0.11, 0.36) −0.11 (−0.40, 0.18) 0.155
6 to 12 months −0.13 (−0.39, 0.14) 0.22 (−0.10, 0.54) 0.062
Delta subregion
0 to 3 months 0.04 (−0.12, 0.19) 0.00 (−0.17, 0.17) 0.859
3 to 6 months 0.09 (−0.12, 0.30) −0.11 (−0.40, 0.18) 0.155
6 to 12 months −0.05 (−0.27, 0.16) 0.22 (−0.10, 0.54) 0.064
MTFJ Baseline 1.6 (1.1, 2.2) 1.1 (0.3, 1.9) 0.418
Delta sum
0 to 3 months −0.11 (−0.41, 0.20) −0.11 (−0.49, 0.27) 0.727
3 to 6 months −0.07 (−0.27, 0.13) 0.06 (−0.21, 0.32) 0.530
6 to 12 months 0.07 (−0.21, 0.35) 0.17 (−0.38, 0.71) 0.673
Delta subregion
0 to 3 months −0.07 (−0.30, 0.16) −0.17 (−0.47, 0.14) 0.574
3 to 6 months −0.05 (−0.21, 0.10) 0.06 (−0.21, 0.32) 0.525
6 to 12 months 0.02 (−0.20, 0.24) 0.17 (−0.38, 0.71) 0.646
PFJ Baseline 1.0 (0.5, 1.5) 1.5 (0.1, 2.9) 1.000
Delta sum
0 to 3 months 0.05 (−0.09, 0.20) −0.06 (−0.45, 0.34) 0.772
3 to 6 months −0.09 (−0.24, 0.06) 0.00 (−0.24, 0.24) 0.647
6 to 12 months −0.09 (−0.31, 0.13) 0.06 (−0.38, 0.49) 0.123
Delta subregion
0 to 3 months 0.05 (−0.09, 0.20) −0.06 (−0.45, 0.34) 0.772
3 to 6 months −0.09 (−0.24, 0.06) 0.00 (−0.24, 0.24) 0.647
6 to 12 months −0.11 (−0.32, 0.10) 0.06 (−0.38, 0.49) 0.115
CI confidence interval, LTFJ lateral tibio-femoral joint (includes 5 subregions), MTFJ medial tibio-femoral joint (includes 5 subregions), PFJ patello-femoral joint
(includes 4 subregions). Possible score range for bone marrow lesion is 0–3 for each subregion at baseline, 3-, 6- and 12-month
*Statistically significant at p ≤ 0.05
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course of the disease, and the limited number of patients
in each cohort.
Limitations of our post-hoc analysis include the small
sample size, and therefore corresponding lack of mul-
tiple adjustment in addition to not handling of missing
data. Further, we only used matched, rather than all,
placebo patients for comparison with the 100 μg cohort,
because this was an ascending dose escalation safety
study, and in which each of the 10, 30 and 100 μg cohort
were randomized and matched with a placebo control at
different times throughout the study.
Conclusions
In summary, positive effects on the patello-femoral
cartilage from baseline to 12 months and on BMLs in
whole knee analyses were seen from 6 to 12 months.
Continued clinical and basic studies are warranted to
understand better the potential effects of sprifermin on
different joint structures.
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osteoarthritis; PFJ, patello-femoral joint; qMRI, quantita-
tive MRI; SD, standard
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